复方丹参注射液联合西医治疗慢性肺源性心脏病心力衰竭疗效的Meta分析  

The Effect of Compound Danshen Injection Combined with Western Medicine for the Treatment of Cor Pulmonale and Heart Failure:a Meta-analysis

作　　者：张赤道 吴文俊 邢作英[2] 卫靖靖 朱明军[2] 王永霞[2] ZHANG Chidao;WU Wenjun;XING Zuoying;WEI Jingjing;ZHU Mingjun;WANG Yongxia(Henan University of Chinese Medicine,Zhengzhou 450046,Henan,China;不详)

机构地区：[1]河南中医药大学,郑州450046 [2]河南中医药大学第一附属医院,郑州450000

出　　处：《中西医结合心脑血管病杂志》2024年第5期786-794,共9页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家自然科学基金项目(No.82074229)。

摘　　要：目的:系统评价复方丹参注射液联合西医治疗肺源性心脏病心力衰竭的有效性和安全性。方法:检索中国知网、万方、维普、中国生物医学文献服务系统(SinoMed)、PubMed、the Cochrane Library、EMbase等数据库建库至2022年10月1日有关复方丹参注射液联合西医治疗肺源性心脏病心力衰竭的随机对照试验(RCT)。依据纳入及排除标准筛选得到相关文献,使用RevMan 5.4和Stata 14.0对纳入研究进行Meta分析。结果:共纳入29篇文献,涉及2879例病人,其中试验组1456例,对照组1423例。试验组总有效率高于对照组[RR=1.29,95%CI(1.25,1.34),P<0.001];试验组心率减慢时间[WMD=-3.08,95%CI(-3.66,-2.51),P<0.00001]、发绀缓解时间[WMD=-2.00,95%CI(-2.72,-1.28),P<0.00001]、水肿消退时间[WMD=-2.23,95%CI(-2.51,-1.96),P<0.00001]短于对照组;试验组血流动力学指标血细胞比容[WMD=-17.36,95%CI(-29.33,-5.39),P=0.004]、全血高切黏度[WMD=-1.55,95%CI(-2.03,-1.07),P<0.00001]、全血低切黏度[WMD=-3.04,95%CI(-3.91,-2.17),P<0.001]、血浆黏度[WMD=-0.21,95%CI(-0.23,-0.19),P<0.00001]、纤维蛋白原[WMD=-0.71,95%CI(-1.03,-0.39),P<0.001]低于对照组。结论:现有证据表明,复方丹参注射液联合西医治疗肺源性心脏病心力衰竭疗效显著且安全性较好。Objective:To systematically evaluate the efficacy and safety of Compound Danshen Injection combined with western medicine for the treatment of cor pulmonale and heart failure.Methods:Randomized controlled trials of Compound Danshen Injection combined with western medicine for the treatment of cor pulmonale and heart failure from the database establishment to October 1,2022 were searched from CNKI,WanFang,VIP,SinoMed,PubMed,the Cochrane Library,EMbase and other databases.Inclusion and exclusion criteria were used to select the final included literatures.RevMan 5.3 software and Stata 14.0 were used for Meta-analysis.Results:A total of 29 literatures were included,including 2879 patients,with 1456 patients in the experimental group and 1423 patients in the control group.The results of Meta-analysis showed that compared with the control group,the total clinical efficacy of the experimental group was higher than that of the control group(RR=1.29,95%CI 1.25-1.34,P<0.001).Heart rate slowing time(WMD=-3.08,95%CI-3.66--2.51,P<0.00001),cyanosis remission time(WMD=-2.00,95%CI-2.72--1.28,P<0.00001),edema regression time(WMD=-2.23,95%CI-2.51--1.96,P<0.00001)in the experimental group were lower than those in the control group.Hemodynamic index hematocrit(WMD=-17.36,95%CI-29.33--5.39,P=0.004),whole blood high tangential viscosity(WMD=-1.55,95%CI-2.03--1.07,P<0.00001),whole blood low shear viscosity(WMD=-3.04,95%CI-3.91--2.17,P<0.001),plasma viscosity(WMD=-0.21,95%CI-0.23--0.19,P<0.00001),fibrinogen(WMD=-0.71,95%CI-1.03--0.39,P<0.001)in the experimental group were lower than those in the control group.Conclusion:The current evidence showed that Compound Danshen Injection combined with western medicine for the treatment of cor pulmonale and heart failure was effective and safe.

关 键 词：肺源性心脏病 心力衰竭 复方丹参注射液 疗效 META分析 

分 类 号：R541.5[医药卫生—心血管疾病] R541.6[医药卫生—内科学]